CHMP Issues Positive Opinion for Merck's VICTRELIS, Oral Hepatitis C Virus (HCV) Protease Inhibitor

[Guest guest]

CHMP Issues Positive Opinion for Merck's VICTRELIS, Oral Hepatitis C Virus (HCV)

Protease Inhibitor

From the PharmaLive.com News Archive - May. 20, 2011

Merck, known as MSD outside the United States and Canada, today announced that

the Committee for Medicinal Products for Human Use (CHMP) of the European

Medicines Agency (EMA) has adopted a positive opinion under accelerated

assessment1 recommending approval of the investigational medicine VICTRELIS

(boceprevir) for the treatment of chronic hepatitis C virus (HCV) genotype 1

infection, in combination with peginterferon alfa and ribavirin, in adult

patients with compensated liver disease who are previously untreated or who have

failed previous therapy.

[Guest guest]

CHMP Issues Positive Opinion for Merck's VICTRELIS, Oral Hepatitis C Virus (HCV)

Protease Inhibitor

From the PharmaLive.com News Archive - May. 20, 2011

Merck, known as MSD outside the United States and Canada, today announced that

the Committee for Medicinal Products for Human Use (CHMP) of the European

Medicines Agency (EMA) has adopted a positive opinion under accelerated

assessment1 recommending approval of the investigational medicine VICTRELIS

(boceprevir) for the treatment of chronic hepatitis C virus (HCV) genotype 1

infection, in combination with peginterferon alfa and ribavirin, in adult

patients with compensated liver disease who are previously untreated or who have

failed previous therapy.